Clinical trial Recruiting at 4 sites Observational Women only

Safety of Ultomiris during pregnancy

Official title: Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Run by Alexion Pharmaceuticals, Inc. · NCT06312644 · Data updated 2026-11-12

This study looks at how safe Ultomiris is for pregnant women and their babies to see if it causes any problems during pregnancy and breastfeeding.

Quick facts

Study typeObservational
SexWomen only
Enrollment75 (estimated)
SponsorAlexion Pharmaceuticals, Inc.
Industry-sponsored
Locations7 sites (Boston, Massachusetts and 6 other locations)
StatusRecruiting
StartedDecember 16, 2024
Main results expectedJuly 11, 2034
Study endsJuly 11, 2034
Registry record updatedApril 16, 2026
Trial IDNCT06312644 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women who have been exposed to Ultomiris and have a qualifying medical condition.

Probably not a fit

Patients who are not pregnant or have not been exposed to Ultomiris will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on pregnancy outcomes and maternal complications in women exposed to Ultomiris during pregnancy and breastfeeding. It will assess both maternal health and the effects on the developing fetus and infant through the first year of life. The study will collect both prospective and retrospective data to provide a comprehensive understanding of the risks associated with Ultomiris exposure in these populations.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the safety of Ultomiris for pregnant women and their infants, potentially guiding treatment decisions.

How similar studies have gone: While studies on drug safety during pregnancy are common, this specific focus on Ultomiris exposure is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female participant must have a medically confirmed qualifying pregnancy (prospectively or retrospectively identified).
* Participant informed consent (written or e-consent per local regulations or ethics committee requirements) must be obtained prior to the participant's enrollment. If the participant is a minor, consent must be obtained from the parent or legal guardian, with assent from the minor (as locally appropriate).
* Willing to provide contact information for the participant.
* Willing to authorize HCP(s) to release maternal and infant medical information to the study, upon request, if applicable to current local regulations.
* Diagnosed with an indication for which Ultomiris is approved, based on HCP or medical records.
* Exposed to Ultomiris at any point during the defined exposure window based on HCP or medical record documentation. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester or timing of exposure \[prior to conception as LMP+14 days, or during breastfeeding\].)
* Use of Ultomiris per local product information (i.e., United States Prescribing Information \[USPI\] or summary of product characteristics \[SmPC\])

Exclusion Criteria:

* Participants who are unable to provide consent or assent (as locally appropriate) (e.g., diagnosed with severe psychiatric conditions or severe intellectual disabilities) will be excluded from this study

Where it's running

  • Research Site
    Boston, Massachusetts, United States
    Recruiting
  • Research Site
    Paris, France
    Recruiting
  • Research Site
    Essen, Norte-Westfalia, Germany
    Recruiting
  • Research Site
    Rome, Italy
    Recruiting
  • Research Site
    Melbourne, Victoria, Australia
    Not yet recruiting
  • Research Site
    Seoul, South Korea
    Active not recruiting
Show 1 more location
  • Research Site
    London, United Kingdom
    Active not recruiting

Study contacts

  • Principal investigator: Sydney Williams — North American Coordinating Center (NACC)
  • Study coordinator: Alexion Pharmaceuticals, Inc. (Sponsor)
  • Email: clinicaltrials@alexion.com
  • Phone: 1-855-752-2356

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.